Becton Dickinson, a leading medical-device maker, has announced its financial results for the fiscal fourth quarter. The company experienced widespread growth across its various segments, driving higher sales and solid performance.
Robust Sales Figures
In the three months ended September 30, Becton Dickinson reported a profit of $108 million, or 37 cents per share. While this was lower than the previous year’s figure of $265 million, or 92 cents per share, it is important to note that the decline can be attributed to factors such as discontinued operations and product-remediation costs. When adjusting for these one-time items, the adjusted earnings were $3.42 per share, in line with analysts’ expectations.
Impressive Revenue Growth
Becton Dickinson also saw a notable increase in revenue, with a nearly 7% rise to $5.09 billion. This surpassed the estimated revenue of $5.02 billion by analysts surveyed by FactSet. Demonstrating a strong performance both domestically and internationally, U.S. sales grew by over 6%, while international sales rose by nearly 8%. Furthermore, the company’s base business, which excludes Covid-testing sales, experienced growth of more than 7%.
Within its different segments, Becton Dickinson witnessed positive results. The medical unit saw sales increase by almost 8%, reaffirming the company’s strong presence in this area. In addition, the life-sciences revenue climbed by 3%, reflecting steady growth and market demand. The interventional segment also performed well, with sales totaling $1.2 billion, marking a substantial increase of almost 10% compared to the same period last year.
These impressive sales figures not only highlight Becton Dickinson’s financial strength but also underscore its commitment to delivering quality healthcare solutions.
To learn more about Becton Dickinson’s financial performance, please contact the company directly.